Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Greater Cannabis CoGCAN +23.76%30 EV-to-OCF is -13.13 as of Aug. 27, 2026. GuruFocus rates GCAN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Greater Cannabis Co ranks better than 83.9% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Greater Cannabis Co's Enterprise Value is $0.53 Mil.
Greater Cannabis Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.04 Mil. Therefore, Greater Cannabis Co's EV-to-OCF for today is -13.13.
The historical rank and industry rank for Greater Cannabis Co's EV-to-OCF or its related term are showing as below:
GCAN'
s EV-to-OCF Range Over the Past 10 Years
Min: -14.88 Med: -1.84 Max: 1.48
Current: -13.13
During the past 10 years, the highest EV-to-OCF of Greater Cannabis Co was 1.48. The lowest was -14.88. And the median was -1.84.
GCAN's EV-to-OCF is ranked better than 83.9% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.54
vs GCAN: -13.13
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Greater Cannabis Co (OTCPK:GCAN) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Greater Cannabis Co's PE Ratio (TTM) for today is calculated as:
Greater Cannabis Co's share price for today is $0.25.
Greater Cannabis Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Greater Cannabis Co EV-to-OCF Related Terms
Greater Cannabis Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Greater Cannabis Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Greater Cannabis Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greater Cannabis Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Greater Cannabis Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Greater Cannabis Co's EV-to-OCF falls into.
Greater Cannabis Co's current Enterprise Value is $0.53 Mil.
Greater Cannabis Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greater Cannabis Co (GCAN) has a EV-to-OCF of -13.13 as of Aug. 27, 2026. According to the industry distribution chart, Greater Cannabis Co ranks #162 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 16.1%.
Is Greater Cannabis Co's EV-to-OCF too high?
Greater Cannabis Co's current EV-to-OCF is -13.13. Based on the distribution chart, Greater Cannabis Co ranks #162 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Greater Cannabis Co has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Greater Cannabis Co's EV-to-OCF compare to STEK and KAYS?
According to the Drug Manufacturers industry distribution chart, Greater Cannabis Co ranks #162 out of 1006 companies for EV-to-OCF. This places Greater Cannabis Co in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.54, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greater Cannabis Co's current EV-to-OCF is -13.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greater Cannabis Co stock overvalued right now?
Greater Cannabis Co (GCAN) has a current EV-to-OCF of -13.13. The current EV-to-OCF is -13.13. Greater Cannabis Co's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Greater Cannabis Co (GCAN), the current EV-to-OCF is -13.13 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greater Cannabis Co Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a pharma-grade therapeutic that reduces disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications. The company is focused on developing new formulations around cannabinoid therapeutics.
30GF Score
Get the complete analysis for GCAN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GCAN has been successfully added to your 
